Skip to main content
OpenTrials
Completed

NCT Number: NCT05096403

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

The purpose of the study is to determine the efficacy of pegcetacoplan administration compared to placebo in increasing hemoglobin (Hgb) level from baseline and avoiding transfusion in participants with primary cold agglutinin disease (CAD).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cold Agglutinin Disease Anemia Anemia, Hemolytic Anemia, Hemolytic, Autoimmune Autoimmune Diseases Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Medical University, Vienna, Austria

Loading trial locations.

About this study

This is a blind (actual treatment not disclosed to Investigator or participant) study to study pegcetacoplan in people with cold agglutinin disease. The study will consist of a 4-week screening period where selected tests will be conducted to ensure that the patient is eligible to participate in the study, followed by Part A, a 24-week blinded treatment period where the participants will receive either pegcetacoplan or a placebo treatment, looking like pegcetacoplan but with no effect. After this period, the participants will move into Part B, a 24-week period where they will all receive pegcetacoplan. Part C is a 48-week maintenance period with pegcetacoplan for all participants. After the end of treatment participants will undergo a safety follow visit about 8 weeks after last dose.

All eligible study participants will receive pegcetacoplan or placebo treatment, administered via subcutaneous infusion twice a week at home. The subcutaneous infusion requires two small needles to be inserted into the fatty layer of tissue under the skin and the investigational medication will flow into the body. Study participants and/or caregivers will be trained on home administration of pegcetacoplan.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older.
  • Diagnosis of primary CAD.
  • Hb level ≤ 9 g/dL.
  • Documented results from bone marrow biopsy within 1 year of screening
  • Either have vaccination against Streptococcus pneumoniae, Neisseria meningitidis (Types A, C, W, Y, and B), and Haemophilus influenzae (Type B) within 2 years prior to screening or agree to receive vaccination during screening.
  • Women of childbearing potential (WOCBP), defined as any women who have experienced menarche and who are NOT permanently sterile or postmenopausal, must have a negative pregnancy test at screening and agree to use protocol-defined methods of contraception for the duration of the study and 8 weeks after their last investigational medicinal product (IMP) dose.
  • Men must agree to the following for the duration of the study and 8 weeks after their last IMP dose:
  • Avoid fathering a child.
  • Use protocol-defined methods of contraception.
  • Refrain from donating sperm.
  • Willing and able to give written informed consent.

Exclusion criteria

  • Have received other anti-complement therapies (approved or investigational) within 5 half-lives of the agent prior to randomization.
  • Treatment with rituximab monotherapy within 12 weeks prior to randomization, or rituximab combination therapies (e.g., with bendamustine, fludarabine, other cytotoxic drugs or ibrutinib) within 16 weeks prior to randomization.
  • Diagnosis of systemic lupus erythematosus or other autoimmune diseases with antinuclear antibodies.
  • History of an aggressive lymphoma or presence of a lymphoma requiring therapy.
  • Have received an organ transplant.
  • Cold agglutinin syndrome secondary to Mycoplasma pneumoniae, Epstein-Barr virus or other specific causative infection.
  • Presence or suspicion of liver dysfunction as indicated by elevated alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN), or direct bilirubin levels > 2 x ULN.
  • Inability to cooperate with study procedures.

Treatment and study plan

Pegcetacoplan

Drug

Pegcetacoplan taken twice weekly as subcutaneous injection

Other names: Aspaveli, Empaveli

Placebo matching Pegcetacoplan

Drug

Placebo matching pegcetacoplan taken twice weekly as subcutaneous injection

Primary outcomes

  1. Number of Patients Achieving a Response (R) at Week 24

    Time frame: Week 24

    A participant was considered to have a response if the Hgb level increased greater than or equal to (>=) 1.5 gram per deciliter (g/dL) from baseline and this increase was maintained from Week 16 through Week 24 in absence of blood transfusion from Week 5 through Week 24.

Secondary outcomes

  1. Change From Baseline to Week 24 in Hemoglobin (Hgb) Level-Part A in the Absence of Intercurrent Events (ICEs).

    Time frame: Week 24

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) Mean change from Baseline to Week 24 in Hemoglobin (Hgb) level.

  2. Number of Patients Achieving Transfusion Avoidance From Week 5 to Week 24-Part A

    Time frame: Week 24

    Percentage of patients who did not receive a blood transfusion between Week 5 and Week 24 was assessed

  3. Change From Baseline to Week 24 in FACT-An Scale Score (Quality of Life)-Part A in the Absence of Intercurrent Events (ICEs)

    Time frame: Week 24

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    FACT-An is used to measure quality of life (QoL) in patients with anemia. Each item is rated on a 5-point Likert scale:0=Not at all, 1=A little bit ,2=Somewhat, 3=Quite a bit, 4=Very much. Some items are reverse scored. Higher scores in this scale denote a better QoL with less impact of anemia.The total FACT-An scale score ranges from 0 to 160. The total score gives a comprehensive view of a patient's well-being. It combines the FACT-G with an Anemia subscale. FACT-G (27 items):Physical Well-Being (PWB) and Social/Family Well-Being (SWB) 14 items in total, Emotional Well-Being (EWB)-6 items,Functional Well-Being (FWB)-7 items, Anemia Subscale (AnS): 13 items. Total FACT-An score=FACT-G + Anemia Subscale=40 item

  4. Number of Packed Red Blood Cell Transfusions Received by Patients From Week 5 to Week 24-Part A

    Time frame: Week 24

    Number of blood transfusions received between Week 5 and Week 24 were assessed.

  5. Change From Baseline to Week 24 in LDH Levels-Part A in the Absence of Intercurrent Events (ICEs)

    Time frame: Week 24

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) Mean change from baseline to Week 24 in Lactate dehydrogenase (LDH) levels

  6. Change From Baseline to Week 24 in Haptoglobin Levels-Part A in the Absence of Intercurrent Events (ICEs)

    Time frame: Week 24

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    Mean change from baseline to Week 24 in Haptoglobin level

  7. Change From Baseline to Week 24 in Indirect Bilirubin-Part A in the Absence of Intercurrent Events (ICE)

    Time frame: Week 24

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    Mean change from baseline to Week 24 in Indirect bilirubin level

  8. Change From Baseline to Week 24 in ARC-Part A in the Absence of Intercurrent Events (ICEs)

    Time frame: Week 24

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    Mean change from baseline to Week 24 in Absolute reticulocyte counts (ARC).

  9. Change From Baseline to Week 24 in D-dimer Levels-Part A in the Absence of Intercurrent Events (ICEs

    Time frame: Week 24

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) change from baseline to Week 24 in D-dimer levels.

  10. Normalization of Markers of Hemolysis (LDH) at Week 24-Part A

    Time frame: Week 24

    Percentage of patients with LDH level within normal ranges and with an abnormal value at baseline.

  11. Normalization of Markers of Hemolysis (Indirect Bilirubin) at Week 24-Part A

    Time frame: Week 24

    Percentage of patients with Indirect Bilirubin level within normal ranges and with an abnormal value at baseline.

  12. Normalization of Markers of Hemolysis (ARC) at Week 24-Part A

    Time frame: Week 24

    Percentage of patients with ARC level within normal ranges and with an abnormal value at baseline.

  13. Normalization of Markers of Hemolysis (Haptoglobin) at Week 24-Part A

    Time frame: Week 24

    Percentage of patients with haptoglobin level within normal ranges and with an abnormal value at baseline.

  14. Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Haptoglobin Levels-Part A

    Time frame: Week 24

    Percentage of patients with haptoglobin level normalization during the initial 24 weeks of the study

  15. Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Hemoglobin Levels-Part A

    Time frame: Week 24

    Percentage of patients with Hemoglobin level normalization during the initial 24 weeks of the study

  16. Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for LDH Levels-Part A

    Time frame: Week 24

    Percentage of patients with LDH level normalization during the initial 24 weeks of the study

  17. Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Indirect Bilirubin Levels-Part A

    Time frame: Week 24

    Percentage of patients with Indirect Bilirubin level normalization during the initial 24 weeks of the study

  18. Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for ARC Levels-Part A

    Time frame: Week 24

    Percentage of patients with ARC level normalization during the initial 24 weeks of the study

  19. Number of Packed Red Blood Cell Units Transfused From Week 5 to Week 24-Part A

    Time frame: Week 5 to Week 24

    Number of PRBC units transfused from Week 5 and Week 24 was assessed

  20. Change From Baseline to Week 24 in FACIT-F Subscale Score-Part A in the Absence of Intercurrent Events (ICEs)

    Time frame: Week 24

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    The FACIT-F subscale is used to measure fatigue and its impact upon daily activities and function in patients with chronic illnesses and contains 20 items related to the impact of fatigue. Each item is scored on a 0-4 scale, with some items reverse-scored. Total scores range from 0 to 52, where higher scores indicate less fatigue and better outcomes, and lower scores reflect greater fatigue. It can be used alone or with other FACIT subscales as part of broader quality of life assessments.

  21. Change From Baseline to Week 24 in SF-12-Part A in the Absence of Intercurrent Events (ICEs)

    Time frame: Week 24

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange.

    SF-12 is a 12-item health survey assessing physical and mental health. Higher scores mean better health with scores above 50 indicating better than average health. It produces two summary scores: the Physical Component Summary (PCS) and Mental Component Summary (MCS), both norm-based (mean=50, SD=10), with ranges of ~5-80 (PCS) and ~-3.3-80 (MCS). Higher scores=better health. It also covers 8 subscales-Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH), each scored between 0-100, where higher=better functioning. Scores are computed using weighted formulas from item responses (not simple averages).

  22. Change From Baseline to Week 24 in EQ-5D-5L Questionnaire -Part A in the Absence of Intercurrent Events (ICEs)

    Time frame: Week 24

    The EQ-5D-5L measures total health across 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression-each scored from 1 (no problems) to 5 (extreme problems). Scores form a 5-digit health profile (e.g., 12345). Each individual score plus a VAS for perceived health status today are separately reported. Higher scores reflect better total health. The EQ VAS is a patient-rated score from 0 (worst) to 100 (best health).

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

  23. Change From Baseline to Week 48 in Hemoglobin (Hgb) Level-Part B in the Absence of Intercurrent Events (ICEs).

    Time frame: Week 48

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    Mean change from Baseline to Week 48 in Hemoglobin (Hgb) level.

  24. Change From Baseline to Week 48 in LDH Level-Part B in the Absence of Intercurrent Events (ICEs).

    Time frame: Week 48

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    Mean change from Baseline to Week 48 in LDH level.

  25. Change From Baseline to Week 48 in Haptoglobin Level-Part B in the Absence of Intercurrent Events (ICEs).

    Time frame: Week 48

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    Mean change from Baseline to Week 48 in Haptoglobin level

  26. Change From Baseline to Week 48 in Indirect Bilirubin Level-Part B in the Absence of Intercurrent Events (ICEs).

    Time frame: Week 48

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    Mean change from Baseline to Week 48 in Indirect Bilirubin level.

  27. Change From Baseline to Week 48 in ARC-Part B in the Absence of Intercurrent Events (ICEs)

    Time frame: Week 48

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    Mean change from baseline to Week 48 in Absolute reticulocyte counts (ARC).

  28. Change From Baseline to Week 48 in D-dimer Levels-Part B in the Absence of Intercurrent Events (ICEs).

    Time frame: Week 48

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    Mean change from baseline to Week 48 in D-dimer levels.

  29. Change From Baseline to Week 48 in FACT-An Scale Score (Quality of Life)-Part B in the Absence of Intercurrent Events (ICEs)

    Time frame: Week 48

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug and plasma exchange.

    The FACT-An is used to measure quality of life (QoL) in patients with anemia. Each item is rated on a 5-point Likert scale:0=Not at all, 1=A little bit ,2=Somewhat, 3=Quite a bit, 4=Very much.Some items are reverse scored. Higher scores in this scale denote a better QoL with less impact of anemia. The total FACT-An scale score ranges from 0 to 160. The total score gives a comprehensive view of a patient's well-being. It combines the FACT-G with an Anemia subscale.FACT-G (27 items):Physical Well-Being (PWB) and Social/Family Well-Being (SWB) 14 items in total, Emotional Well-Being (EWB)-6 items, Functional Well-Being (FWB)-7 items, Anemia Subscale (AnS): 13 items. Total FACT-An score=FACT-G + Anemia Subscale=40 items

  30. Change From Baseline to Week 48 in FACIT-F Subscale Score-Part B in the Absence of Intercurrent Events (ICEs).

    Time frame: Week 48

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    The FACIT-F subscale is used to measure fatigue and its impact upon daily activities and function in patients with chronic illnesses and contains 20 items related to the impact of fatigue. Each item is scored on a 0-4 scale, with some items reverse-scored. Total scores range from 0 to 52, where higher scores indicate less fatigue and better outcomes, and lower scores reflect greater fatigue. It can be used alone or with other FACIT subscales as part of broader quality of life assessments.

  31. Change From Baseline to Week 48 in EQ-5D-5L-Part B in the Absence of Intercurrent Events (ICEs).

    Time frame: Week 48

    The EQ-5D-5L measures total health across 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression-each scored from 1 (no problems) to 5 (extreme problems). Scores form a 5-digit health profile (e.g., 12345). Each individual score plus a VAS for perceived health status today are separately reported. Higher scores reflect better total health. The EQ VAS is a patient-rated score from 0 (worst) to 100 (best health).

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

  32. Change From Baseline to Week 48 in SF-12-Part B in the Absence of Intercurrent Events (ICEs).

    Time frame: Week 48

    The ICEs of interest were :

    • Withdrawal from treatment or lost to follow-up before the end of the double-blind period
    • Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange SF-12 is a 12-item health survey assessing physical and mental health. Higher scores mean better health with scores above 50 indicating better than average health. It produces two summary scores: the Physical Component Summary (PCS) and Mental Component Summary (MCS), both norm-based (mean = 50, SD =10), with ranges of ~5-80 (PCS) and ~-3.3-80 (MCS). Higher scores = better health. It also covers 8 subscales-Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH), each scored between 0-100, where higher=better functioning. Scores are computed using weighted formulas from item responses (not simple averages).

Sponsors and collaborators

Lead sponsor

Swedish Orphan Biovitrum

Industry

Registry information

Official study title

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Oct 27, 2021
Registry last updated
Oct 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.